Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer

PLoS ONE - United States
doi 10.1371/journal.pone.0052095
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Class II Histone Deacetylases Are Directly Recruited by BCL6 Transcriptional Repressor

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2002English

Ssn6-Tup1 Interacts With Class I Histone Deacetylases Required for Repression

Genes and Development
GeneticsDevelopmental Biology
2000English

Class II Histone Deacetylases Are Associated With VHL-Independent Regulation of Hypoxia-Inducible Factor 1α

Cancer Research
Cancer ResearchOncology
2006English

Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue

Neuropsychopharmacology
PsychiatryMental HealthPharmacology
2015English

Histone Deacetylases as Targets for Antitrypanosomal Drugs

Future Science OA
MedicineBiotechnology
2018English

Misfolded Proteins Complexed With MHC Class II Molecules Are Targets for Autoantibodies

Japanese Journal of Clinical Immunology
2016English

Histone Deacetylases as Targets for Treatment of Multiple Diseases

Clinical Science
Medicine
2013English

Transcription and Beyond: The Role of Mammalian Class I Lysine Deacetylases

Chromosoma
Genetics
2013English

A Class of Hybrid Polar Inducers of Transformed Cell Differentiation Inhibits Histone Deacetylases

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1998English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy